What is CMV Drug Resistance Testing?
Helping Pharma companies develop Precision medicine using Clinical Data & AI.
What is CMV Drug Resistance Testing?
Cytomegalovirus (CMV) is a common virus that can cause severe complications in immunocompromised individuals, such as transplant recipients or those with HIV/AIDS. When standard antiviral treatments fail, it is often due to genetic mutations conferring drug resistance. GeneHealth’s CMV Drug Resistance Test utilizes advanced Next-Generation Sequencing (NGS) to rapidly identify specific mutations in the CMV genome, empowering clinicians to tailor targeted antiviral therapies effectively.
Book a Test Now →Gene Coverage in CMV Drug Resistance Testing
| Gene | Function / Resistance Profile |
|---|---|
| UL97 | Associated with Ganciclovir and Valganciclovir resistance. |
| UL54 | Associated with Foscarnet and Cidofovir resistance (DNA Polymerase mutations). |
| UL56 | Associated with Letermovir resistance. |
Key Benefits of the Test
- Guides appropriate and targeted antiviral drug selection.
- Prevents disease progression in refractory or recurrent CMV infections.
- Helps customize antiviral dosing and treatment duration.
- Improves overall patient outcomes, particularly in vulnerable post-transplant scenarios.
Specifications
Diseases & Disorders Detected
Clinical scenarios where CMV resistance testing is crucial.
- Cytomegalovirus (CMV) Infection
- Congenital CMV
- CMV Retinitis
- CMV Pneumonia
- CMV Gastroenteritis
- Immunosuppression (e.g., Solid Organ or Stem Cell Transplant recipients, HIV/AIDS)
- Primary Immunodeficiency
- Post-transplant Viral Complications
Key Highlights of GeneHealth’s CMV Test
Advanced NGS technology detects even low-frequency genetic mutations conferring resistance to standard antiviral medications.
Critical for transplant recipients and immunocompromised individuals, ensuring effective viral suppression and reducing the risk of severe complications.
Identifies mutations across key viral genes (UL97, UL54, and UL56) that are heavily correlated with drug resistance in CMV patients.
